Search Results

Indications for use include:

· The blue light (415nm wavelength) indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.

· The red light (633nm wavelength) indicated for treatment of superficial, benign, vascular and pigmented lesions.

• The near-infrared light (830nm wavelength) is generally indicated for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

The Dermalux Tri-Wave MD MK II & Dermalux Compact MD is a Medical Device (MDR Class II) which emits specific wavelengths of low level, narrow band light for the treatment of certain aesthetic, dermatological and medical indications. The wavelengths used in the Tri-Wave MD MK II & Compact MD systems are Blue 415nm, Red 633nm and Near Infrared 830nm. The Dermalux professional use family consists of the Tri-Wave MD MKI; a floor standing unit with 4 pod treatment head, Compact MD; desk mounted unit with a 3 pod treatment head.

The system enables treatment of the body via an articulated 4 or 3 panel LED head. The panels can be easily adjusted for focused intensity treatments and application to larger body areas.

The system consists of a main body that contains the power supply (100-240Vac, 50/60Hz), power switch, touch screen control panel and a 4 or 3 panel adjustable treatment head that contains Light Emitting Diodes (LEDs).

The power supply is designed to power the internal electronics for the system and the Light Emitting Diodes. The power supply is connected to a suitable mains outlet. The device is switch located below the screen in the base unit.

The Tri-Wave MD MK II & Compact MD system is operated by a full colour capacitive touch screen which features pre-set and post treatment protocols that can be customised with three power settings. Bespoke protocols can be programmed based on delivered energy or time. The device cannot be networked or connect to the internet, software updates can be performed via a USB flash drive (thumb drive) if required.

The light is generated by Light Emitting Diodes (LED's) which a treatment head. The treatment head is connected to the main body by articulating arm mechanism. The arm allows the operator to correctly position the LED head ment area.

Protective eye wear is supplied with each Dermalux unit for patient and operator comfort.

The Dermalux systems are not used to make measurements of any sort, or to draw any conclusions regarding the indication to treat. The equipment does not require checks on the light output as the LEDs do not dim with age to any practical extent.

The provided text is a 510(k) summary for the Dermalux Tri-Wave MD MKII and Dermalux Compact MD devices. It details the device descriptions, intended use, and a comparison to a predicate device (Dermalux Tri-Wave MD, K200659).

However, this document does not contain information about acceptance criteria for device performance, nor details of specific studies that prove the device meets such criteria. It's a regulatory submission affirming substantial equivalence to a predicate device, based on similar technology and indications for use. It states that "The conclusions drawn from the noncinical tests that demonstrate that the device is as safe, as effective, and performs as well as or better than the legally marketed device identified in paragraph (a)(3) of this section," but it does not provide the details of those non-clinical tests, their results, or any acceptance criteria.

Therefore, I cannot fulfill your request for the specific details about acceptance criteria and performance studies, including sample sizes, ground truth establishment, or expert involvement, as this information is not present in the provided text.

The document mainly focuses on:

• Device Identification: Dermalux Tri-Wave MD MKII (1000021) and Dermalux Compact MD (1000024).
• Intended Use/Indications for Use:
  • Blue light (415nm): Treat moderate inflammatory acne vulgaris.
  • Red light (633nm): Treatment of superficial, benign, vascular and pigmented lesions.
  • Near-infrared light (830nm): Temporary relief of minor muscle and joint pain, arthritis, muscle spasm; relieving stiffness; promoting relaxation of muscle tissue; temporarily increasing local blood circulation.
• Predicate Device: Dermalux Tri-Wave MD (K200659).
• Technological Comparison: States that the new devices have "the same technological characteristicans for use" as the predicate device.

The document does not describe any specific performance study, acceptance criteria, or statistical measures related to efficacy or performance for this specific submission. It relies on substantial equivalence to the predicate device.

Ask a specific question about this device

The Derrmalux® Tri-Wave MD 's use of the red, blue and infrared regions of the spectrum is intended to emit energy to treat dermatological conditions.

The blue light (415nm wavelength) is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.

The red light (633nm wavelength) is generally indicated for treatment of superficial, benign, vascular and pigmented lesions.

The near-infrared light (830nm wavelength) is generally indicated for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

The Dermalux® Tri-Wave MD is a floor standing Class II medical device which emits specific wavelengths of low level, narrow band light for the treatment of dermatological conditions. The wavelengths used in the Tri-Wave MD system are Blue 415nm, Red 633nm and Near Infrared 830nm.

The device consists of a main body that contains the power supply, power switch, touch screen control panel, and a 4 panel adjustable treatment head that contains Light Emitting Diodes enabling treatment of the face and the body. The panels can be easily adjusted for focused intensity treatments and application to larger body areas.

The provided text is a 510(k) summary for the Dermalux® Tri-Wave MD device. It outlines the administrative information, device description, indications for use, and a comparison to a predicate device. However, it explicitly states under the "VII. PERFORMANCE TESTING" section:

• Animal: No studies were performed.
• Clinical: No studies were performed.

This means that the document does not contain information about a study that proves the device meets specific acceptance criteria based on clinical performance in humans or animals. The performance testing mentioned is "Bench Testing" which refers to verification of the device against design specifications and compliance with international and FDA-recognized consensus standards (e.g., electrical safety, electromagnetic compatibility, software lifecycle, photobiological safety, usability).

Therefore, I cannot provide the requested information regarding:

1. A table of acceptance criteria and reported device performance (as no performance studies are mentioned in a clinical context).
2. Sample size used for the test set and data provenance.
3. Number of experts used and their qualifications.
4. Adjudication method for the test set.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done.
6. If a standalone (algorithm only) performance was done.
7. The type of ground truth used.
8. The sample size for the training set.
9. How the ground truth for the training set was established.

This 510(k) summary focuses on demonstrating substantial equivalence through comparison to a predicate device and compliance with relevant safety and technical standards for a phototherapy system, rather than providing clinical efficacy or performance study data.

Ask a specific question about this device